First patient dosed triggers $50 million milestone payment Mechelen Belgium; 22 November 2016 Galapagos NV Euronext & NASDAQ GLPG reports the first dosing of a patient in the DIVERSITY Phase 3 study with filgotinib in Crohn&apo...
↧